Verrica Pharmaceuticals (VRCA) announced the appointment of Chris Chapman as its Chief Commercial Officer. Most recently, Chapman served as Chief Commercial Officer at Dermavant Sciences
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRCA:
- Verrica Pharmaceuticals Launches Ycanth for treatment of Molluscum in Japan
- YCANTH Phase 3 Wart Study Puts Verrica in Focus While Veeva Extends Its Clinical Footprint
- Verrica announces first patient dosed in program evaluating YCANTH
- Verrica Pharmaceuticals Adds Caligan Partner to Board
- Verrica Pharmaceuticals upgraded to Buy from Hold at Brookline